CVC Capital Partners Eyes Recordati Take-Private for €10.9B

CVC Capital Partners has put forth a substantial non-binding offer to acquire the entirety of Recordati S.p.A., an Italian pharmaceutical firm, in a transaction valued at approximately €10.9 billion. This proposed deal, which translates to €52 per share, signals a significant move by the private equity giant to take the publicly traded entity private.

The move comes as CVC Capital Partners already holds a commanding 53.18% stake in Recordati, having previously secured a controlling interest. The current proposal outlines a voluntary tender offer designed to purchase all remaining shares held by the public, paving the way for Recordati's delisting from the Borsa Italiana.

Recordati officially acknowledged the receipt of this takeover proposal on March 26, 2026. However, the offer is contingent upon several critical steps, including the successful completion of thorough due diligence, the arrangement of necessary financing, and the identification of potential co-investors to participate in the significant undertaking.

This potential acquisition highlights the persistent appetite among private equity firms for strategic investments within the healthcare and pharmaceutical sectors. The global pharmaceutical market, particularly segments focused on rare diseases and specialized treatments, continues to attract substantial capital due to its robust growth potential and defensive characteristics. Recordati, with its dual focus on established pharmaceutical products and a growing portfolio of rare disease therapies, presents a compelling target.

Recordati, headquartered in Milan, operates with a diversified business model. Its revenue streams are primarily divided between pharmaceutical and over-the-counter products (approximately 64.4%) and a crucial segment dedicated to medicines for rare diseases (around 35.6%). The company's rare disease pipeline includes notable treatments such as Isturisa for Cushing syndrome, Qarziba for neuroblastoma, and Carbaglu for hyperammonemia. With a global operational footprint spanning multiple continents and a workforce of roughly 4,450 employees, Recordati possesses considerable international reach.

Should this transaction materialize, it would rank among the most significant private equity-led take-private deals in the pharmaceutical industry in recent memory. Industry observers note that CVC Capital Partners may explore strategic options for Recordati post-acquisition, potentially including the divestment of specific business units, such as the company's rare disease division, to optimize returns.